Literature DB >> 30790545

MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.

Lauren M Moore1, Sun Cho1, Katie L Thoren2.   

Abstract

BACKGROUND: Daratumumab, a therapeutic IgG kappa monoclonal antibody, can cause a false positive interference on electrophoretic assays that are routinely used to monitor patients with monoclonal gammopathies. In this study, we evaluate the ability of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to distinguish daratumumab from disease-related IgG kappa monoclonal proteins (M-protein).
METHODS: Waste clinical samples from 31 patients who were receiving daratumumab and had a history of IgG kappa monoclonal gammopathy were collected. Immunoglobulins were purified from serum and analyzed by MALDI-TOF MS. Mass spectra were assessed for the presence of distinct monoclonal proteins. For samples in which only one monoclonal peak was identified near the expected m/z of daratumumab, the Hydrashift 2/4 Daratumumab Assay was used to confirm the presence of an M-protein.
RESULTS: Using MALDI-TOF MS, daratumumab could be distinguished from M-proteins in 26 out of 31 samples (84%). Results from 2 samples were inconclusive since the M-protein was not detected by the Hydrashift assay and may also be undetectable by MALDI-TOF MS. Comparatively, daratumumab was distinguishable from M-proteins in 14 out of 31 samples (45%) by immunofixation.
CONCLUSIONS: MALDI-TOF MS offers greater specificity compared to immunofixation for distinguishing daratumumab from M-proteins.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Daratumumab; MALDI-TOF mass spectrometry; Monoclonal immunoglobulin; Multiple myeloma

Mesh:

Substances:

Year:  2019        PMID: 30790545      PMCID: PMC6524149          DOI: 10.1016/j.cca.2019.02.017

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  10 in total

1.  Interference of monoclonal antibody therapies with serum protein electrophoresis tests.

Authors:  Christopher R McCudden; Peter M Voorhees; Shirley A Hainsworth; Herbert C Whinna; John F Chapman; Catherine A Hammett-Stabler; Monte S Willis
Journal:  Clin Chem       Date:  2010-10-12       Impact factor: 8.327

2.  A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.

Authors:  John R Mills; Mindy C Kohlhagen; Maria A V Willrich; Taxiarchis Kourelis; Angela Dispenzieri; David L Murray
Journal:  Blood       Date:  2018-06-11       Impact factor: 22.113

3.  Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins.

Authors:  Janneke Ruinemans-Koerts; Cyriel Verkroost; Yvonne Schmidt-Hieltjes; Cees Wiegers; Joyce Curvers; Marc Thelen; Matthijs van Luin
Journal:  Clin Chem Lab Med       Date:  2014-11       Impact factor: 3.694

Review 4.  Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences.

Authors:  Christopher R McCudden; Joannes F M Jacobs; David Keren; Hélène Caillon; Thomas Dejoie; Kristian Andersen
Journal:  Clin Biochem       Date:  2017-08-24       Impact factor: 3.281

5.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Authors:  María-Victoria Mateos; Meletios A Dimopoulos; Michele Cavo; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Polina Kaplan; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna M Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Christopher Chiu; Jianping Wang; Robin Carson; Wendy Crist; William Deraedt; Huong Nguyen; Ming Qi; Jesus San-Miguel
Journal:  N Engl J Med       Date:  2017-12-12       Impact factor: 91.245

6.  The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic.

Authors:  Paolo Milani; David L Murray; David R Barnidge; Mindy C Kohlhagen; John R Mills; Giampaolo Merlini; Surendra Dasari; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2017-06-01       Impact factor: 10.047

Review 7.  Daratumumab for the treatment of multiple myeloma.

Authors:  Cyrille Touzeau; Philippe Moreau
Journal:  Expert Opin Biol Ther       Date:  2017-05-02       Impact factor: 4.388

8.  Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Authors:  Kazunori Murata; Samuel I McCash; Brittany Carroll; Alexander M Lesokhin; Hani Hassoun; Nikoletta Lendvai; Neha S Korde; Sham Mailankody; Heather J Landau; Guenther Koehne; David J Chung; Sergio A Giralt; Lakshmi V Ramanathan; Ola Landgren
Journal:  Clin Biochem       Date:  2016-09-21       Impact factor: 3.281

9.  Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry.

Authors:  John R Mills; Mindy C Kohlhagen; Surendra Dasari; Patrick M Vanderboom; Robert A Kyle; Jerry A Katzmann; Maria A V Willrich; David R Barnidge; Angela Dispenzieri; David L Murray
Journal:  Clin Chem       Date:  2016-08-18       Impact factor: 8.327

10.  Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation.

Authors:  Maria Alice V Willrich; Paula M Ladwig; Bruna D Andreguetto; David R Barnidge; David L Murray; Jerry A Katzmann; Melissa R Snyder
Journal:  Clin Chem Lab Med       Date:  2016-06-01       Impact factor: 3.694

  10 in total
  13 in total

1.  Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

Authors:  Marion Eveillard; Even Rustad; Mikhail Roshal; Yanming Zhang; Amanda Ciardiello; Neha Korde; Malin Hultcrantz; Sydney Lu; Urvi Shah; Hani Hassoun; Eric Smith; Alexander Lesokhin; Sham Mailankody; Ola Landgren; Katie Thoren
Journal:  Br J Haematol       Date:  2020-02-05       Impact factor: 6.998

2.  Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

Authors:  Matthew Ho; Giada Bianchi; Kenneth C Anderson
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-24

3.  Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry.

Authors:  Katie L Thoren; Marion Eveillard; Patrick Chan; Sital Doddi; Sun Cho; Kazunori Murata
Journal:  Clin Biochem       Date:  2019-12-26       Impact factor: 3.281

4.  A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis.

Authors:  Li Liu; Michael R Shurin; Sarah E Wheeler
Journal:  Clin Biochem       Date:  2019-11-11       Impact factor: 3.281

5.  Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.

Authors:  Marion Eveillard; Neha Korde; Amanda Ciardiello; Benjamin Diamond; Alexander Lesokhin; Sham Mailankody; Eric Smith; Hani Hassoun; Malin Hultcrantz; Urvi Shah; Sydney Lu; Meghan Salcedo; Kelly Werner; Jenna Rispoli; Donna Mastey; Ola Landgren; Katie Thoren
Journal:  Clin Chim Acta       Date:  2021-02-02       Impact factor: 3.786

6.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Authors:  Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

7.  Sensitive multiple myeloma disease monitoring by mass spectrometry.

Authors:  Rasa Santockyte; Chelsea Jin; James Pratt; Ron Ammar; Keyur Desai; Mohan Bolisetty; Prianka Das; Mihaela Popa-McKiver; Oscar Puig
Journal:  Blood Cancer J       Date:  2021-04-29       Impact factor: 11.037

8.  Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study.

Authors:  Hana Vakili; Sharon Koorse Germans; Xiuhua Dong; Ankit Kansagra; Hetalkumari Patel; Alagarraju Muthukumar; Ibrahim A Hashim
Journal:  Diagnostics (Basel)       Date:  2020-04-14

9.  Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.

Authors:  Paolo Milani; Marco Basset; Mario Nuvolone; Francesca Benigna; Lara Rodigari; Francesca Lavatelli; Andrea Foli; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037

10.  Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.

Authors:  David L Murray; Noemi Puig; Sigurdur Kristinsson; Saad Z Usmani; Angela Dispenzieri; Giada Bianchi; Shaji Kumar; Wee Joo Chng; Roman Hajek; Bruno Paiva; Anders Waage; S Vincent Rajkumar; Brian Durie
Journal:  Blood Cancer J       Date:  2021-02-01       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.